Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15042008 | 1.00 | BRD4 (0.60) | BRD4L3MBTL1CYP2C19MEN1KMT2A | |
| SCHEMBL23177805 | 1.00 | BRD4 (0.60) | BRD4L3MBTL1CYP2C19MEN1KMT2A | |
| SCHEMBL15042026 | 1.00 | BRD4 (0.60) | BRD4L3MBTL1CYP2C19MEN1KMT2A | |
| SCHEMBL12668081 | 1.00 | BRD4 (0.60) | BRD4L3MBTL1CYP2C19MEN1KMT2A | |
| SCHEMBL121038 | 1.00 | BRD4 (0.60) | BRD4L3MBTL1CYP2C19MEN1KMT2A | |
| SCHEMBL9368854 | 0.99 | BRD4 (0.62) | BRD4L3MBTL1CYP2C19MEN1KMT2A | |
| SCHEMBL3133394 | 0.94 | BRD4 (0.64) | BRD4L3MBTL1CYP2C19MEN1KMT2A | |
| SCHEMBL12667390 | 0.94 | BRD4 (0.64) | BRD4L3MBTL1CYP2C19MEN1KMT2A | |
| SCHEMBL15042060 | 0.94 | BRD4 (0.68) | BRD4L3MBTL1CYP2C19MEN1KMT2A | |
| SCHEMBL16499289 | 0.91 | BRD4 (0.62) | BRD4L3MBTL1CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 531 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10888533-B2 | Transdermal composition containing donepezil as active ingredient | ICURE PHARMACEUTICAL INC. (KR) | 2021-01-12 | — | — | US | claimed |
| WO-2020118091-A1 | ONDANSETRON IN-ADHESIVE TRANSDERMAL PATCH | STARTON THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | claimed |
| US-10583098-B2 | Topical co-enzyme Q10 formulations and treatment of pain, fatigue and wounds | THLIVERIS, ANDREW T. | 2020-03-10 | — | — | US | claimed |
| US-20190091168-A1 | FORMULATION FOR ENHANCED TRANSDERMAL ABSORPTION OF DRUG | UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY) (KR) | 2019-03-28 | — | — | US | claimed |
| EP-3235494-A1 | TRANSDERMAL PREPARATION CONTAINING DONEPEZIL AS ACTIVE INGREDIENT | Icure Pharmaceutical Inc. (KR) | 2017-10-25 | — | — | EP | claimed |
| US-20170290780-A1 | TRANSDERMAL COMPOSITION CONTAINING DONEPEZIL AS ACTIVE INGREDIENT | ICURE PHARMACEUTICAL INC. (KR) | 2017-10-12 | — | — | US | claimed |
| EP-3193849-A1 | OPIPRAMOL PATCH | Neuroderm, Ltd. (IL) | 2017-07-26 | — | — | EP | claimed |
| WO-2016042413-A1 | OPIPRAMOL PATCH | NEURODERM, LTD. (IL) | 2016-03-24 | — | — | WO | claimed |
| US-20140243765-A1 | PERCUTANEOUSLY ABSORBABLE PREPARATION CONTAINING FENTANYL AND HOMOLOGUE THEREOF | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2014-08-28 | — | — | US | claimed |
| EP-2759294-A1 | PERCUTANEOUSLY ABSORBABLE PREPARATION CONTAINING FENTANYL AND A HOMOLOGUE THEREOF | Transderm Inc. (KR) | 2014-07-30 | — | — | EP | claimed |
| US-20050250804-A1 | Pharmaceutical gel formulations | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-11-10 | — | — | US | claimed |
| US-20050249757-A1 | Pharmaceutical cream formulations | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-11-10 | — | — | US | claimed |
| US-6673841-B2 | TREATMENT OF ERECTILE DYSFUNCTION | WHAN IN PHARM. CO., LTD. (KR) | 2004-01-06 | — | — | US | claimed |
| US-20030125382-A1 | Alprostadil alkyl ester-containing composition for external application | WHAN IN PHARM. CO., LTD. | 2003-07-03 | — | — | US | claimed |
| US-6500440-B1 | PREPARATION COMPRISING ALPROSTADIL IN OILY VEHICLE WITH SKIN PERMEATION ENHANCER, ANTI-IRRITANT AGENT AND THICKENER | WHAN IN PHARM CO., LTD. (KR) | 2002-12-31 | — | — | US | claimed |
| US-6492180-B2 | EXTRACTION THROUGH THE SKIN OR HAIR USING A 2-PYRROLIDONE IN A CARRIER; DRUGS OF ABUSE, CAFFEINE, PRESCRIPTION DRUGS, E.G. ACETAMINOPHEN, METABOLIC ANALYTES, E.G., BLOOD GLUCOSE AND HEAVY METALS, E.G. LEAD, LITHIUM, COPPER AND IRON | TRANSDERM TECHNOLOGIES LLC | 2002-12-10 | — | — | US | claimed |
| US-20020161323-A1 | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent | ACIONT INC. | 2002-10-31 | — | — | US | claimed |
| EP-0813879-B1 | Drug administration composition for iontophoresis | HISAMITSU PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | claimed |
| EP-1090301-B1 | NON-INVASIVE TRANSDERMAL DETECTION OF ANALYTES | TRANSDERM TECHNOLOGIES LLC (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2001097777-A1 | TOPICAL PREPARATION OF ALPROSTADIL FOR THE TREATMENT OF ERECTILE DYSFUNCTION | WHAN IN PHARM. CO. LTD. (KR) | 2001-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250804-A1 | Pharmaceutical gel formulations | CUTA, PIGS, FKBP2 | BRD4 2799/4885L3MBTL1 4178/4885CYP2C19 195/4885 |
| US-20050249757-A1 | Pharmaceutical cream formulations | CUTA, PIGS, NPC1L1 | BRD4 4152/4885L3MBTL1 4332/4885CYP2C19 83/4885 |
| US-20190091168-A1 | FORMULATION FOR ENHANCED TRANSDERMAL ABSORPTION OF DRUG | APP, PSEN2, PSEN1 | BRD4 445/4885L3MBTL1 4568/4885CYP2C19 82/4885 |
| US-10888533-B2 | Transdermal composition containing donepezil as active ingredient | PSEN1, ACHE, CUTA | BRD4 2557/4885L3MBTL1 4742/4885CYP2C19 219/4885 |
| US-20170290780-A1 | TRANSDERMAL COMPOSITION CONTAINING DONEPEZIL AS ACTIVE INGREDIENT | PSEN1, ACHE, CUTA | BRD4 2557/4885L3MBTL1 4742/4885CYP2C19 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.